Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid

Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid

Zhuo-Yue Li,1,2 Yi-Fan Yin,1,2 Yang Guo,1,2 Hui Li,1,2 Mei-Qi Xu,1,2 Man Liu,1,2 Jing-Ru Wang,1,2 Zhen-Han Feng,1,2 Xiao-Chuan Duan,1,2 Shuang Zhang,1,2 Shuai-Qiang Zhang,1,2 Guang-Xue Wang,2 Ai Liao,2 Shu-Min Wang,3 Xuan Zhang1,2 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Deliv...

Full description

Saved in:
Bibliographic Details
Main Authors: Li ZY, Yin YF, Guo Y, Li H, Xu MQ, Liu M, Wang JR, Feng ZH, Duan XC, Zhang S, Zhang SQ, Wang GX, Liao A, Wang SM, Zhang X
Format: article
Language:EN
Published: Dove Medical Press 2020
Subjects:
sorafenib mesoporous silica nanomatrix (msnm@sfn)
flufenamic acid (ffa)
pge2
akr1c1
akr1c3
4t1/luc
hepg2
Medicine (General)
R5-920
Online Access:https://doaj.org/article/5d8d06cbef1d41e084540efd3c785fdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/5d8d06cbef1d41e084540efd3c785fdf

Similar Items